Fund moves

Madrigal Pharmaceuticals (MDGL): William Blair Investment Management, LLC reduced its stake -14K shares

William Blair Investment Management, LLC reduced its stake in Madrigal Pharmaceuticals, per its Q1 2026 13F.

341K
Shares reported · -14K vs prior quarter
0.59%
Disclosed portfolio weight
$178M
Reported value
Holdings as of
Mar 31, 2026
Filed
May 8, 2026

What stands out in this filing

  • 354,220 shares in Q4 2025, 340,519 now (−3.9% in share count).
  • Reported at $178M, 0.59% of the portfolio value in this 13F filing.
  • 5 other tracked managers reported the same kind of change for Q1 2026.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Apr 3, 2026Federal contract · $36K obligatedDepartment of Veterans Affairs awarded MADRIGAL PHARMACEUTICALS, INC.: $36K obligated to date
  2. Apr 22, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 22, 2026, the Board of Directors (the “Board”) of Madrigal Pharmaceuticals, Inc. (the “Company”) completed a process to reclassify the membership of the Board’s three classes of directors to achieve a more equal apportionment of membership among the three classes following its Annual Meeting of Stockholders to be held on June 17, 2026 (the "2026 Annual Meeting").”
  3. May 6, 2026Company filing · Form 8-K · ResultsReported its results

What came next

  1. Jun 5, 2026Federal contract · $30K obligatedDepartment of Veterans Affairs awarded MADRIGAL PHARMACEUTICALS, INC.: $30K obligated to date
  2. Jun 16, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 17, 2026, at the annual meeting of stockholders (the "Annual Meeting") of Madrigal Pharmaceuticals, Inc. (the "Company"), the Company's stockholders approved the Madrigal Pharmaceuticals, Inc. 2026 Stock Plan (the "2026 Stock Plan"), which was previously adopted by the Company's Board of Directors (the "Board").”
  3. Jul 30, 2026Company filing · Form 8-K · ResultsReported its results
  4. Aug 11, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On August 11, 2026, the Board of Directors (the "Board") of Madrigal Pharmaceuticals, Inc. (the "Company") expanded the size of the Board from eight to nine members and, following the recommendation of its Nominating and Governance Committee, elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the Board effective as of August 11, 2026.”
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Madrigal Pharmaceuticals

For Madrigal Pharmaceuticals, OQRO holds 7 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MDGL page.

How this filing works

Explore the data

Common questions

What does this filing report about Madrigal Pharmaceuticals (MDGL) stock?

William Blair Investment Management, LLC reduced its stake in Madrigal Pharmaceuticals, per its Q1 2026 13F. Now 341K shares, $178M reported value, 0.59% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Mar 31, 2026. Filed: May 8, 2026.

What stands out in this filing?

354,220 shares in Q4 2025, 340,519 now (−3.9% in share count). Reported at $178M, 0.59% of the portfolio value in this 13F filing. 5 other tracked managers reported the same kind of change for Q1 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Madrigal Pharmaceuticals recently?

For Madrigal Pharmaceuticals, OQRO holds 7 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the MDGL page.

Does this mean MDGL stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Madrigal Pharmaceuticals

Everything OQRO holds on this company is on its MDGL page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data